FDA’s Final MOU On Interstate Compounding Now Awaits Signatures From States
Pharmacy Group Says FDA Has Underestimated Amount Of Work For MOU
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
